MAPT and Alzheimer disease: As can be seen, the CSF biomarkers levels (ß-amyloid42, t-tau, p-tau) and the neuropsychological evaluation (CDR, MMSE, RBANS.DM) allowed us to identify AD patients from healthy and non-AD participants.